Diffuse Large B-Cell Lymphoma — Trials

Diffuse Large B-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 355
Recruiting: 190
Ph III recruiting: 16
Growth YoY: −11.6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (177)

clinicaltrialsPublishedShowing 1–16 of 16 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05139017	A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)	recruiting	Phase 2 / Phase 3	290	Merck Sharp & Dohme LLCINDUSTRY	26	Sep 25, 2026	clinicaltrials
NCT06091865	A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma(OLYMPIA-3)	recruiting	Phase 3	904	Regeneron Pharmaceuticals